Pharmaceuticals company Innova Captab announced Q2FY26 results Revenue from Operations registered stellar growth of 19.5% to Rs 380.4 crore vs Rs 318.2 crore. Achieved EBITDA of Rs 56.1 crore vs Rs 51.9 crore in Q2 FY25. EBITDA margin for the quarter was 14.7%. PAT for the quarter stood at Rs 29.7 crore PAT margin was 7.8%. Vinay Lohariwala, Managing Director, Innova Captab, said: “Our strategic initiatives continue to deliver measurable outcomes, as evidenced by YoY revenue growth of 19.5% both in Q2 and H1FY26 reaching Rs 380 crore and Rs 732 crore respectively. We witnessed healthy volume growth, underscoring the sustained demand momentum and operational efficiency achieved through our scale-up efforts. During the quarter, our manufacturing capabilities were further strengthened with the successful inspection of our Cephalosporin plant in Baddi by the United Kingdom’s Medicines and Healthcare products Regulatory Agency (UK-MHRA) and of our Jammu facility by the State Service of Ukraine on Medicines and Drugs Control (SMDC). These milestones underscore our adherence to global quality standards and reinforce our presence in key international markets. With multiple growth levers in motion — including substantial room for scale-up, geographic diversification, and a robust product pipeline — we are well-positioned to sustain our growth trajectory and deliver a resilient performance across both our business verticals.” Result PDF